Is Pharma Leveraging the Diagnostic in Targeted Therapy Branding and Communications? - Diaceutics

Is Pharma Leveraging the Diagnostic in Targeted Therapy Branding and Communications?

Mark Reis
Sanna Jousi
Paul J Pfleiderer

Targeted therapy communications present a host of new opportunities and challenges for brand teams. Research has shown that positive diagnostic sentiment among consumers can be leveraged to enhance and optimize targeted therapy communications. But until now no reports have studied the communication styles pharma has used in targeted therapy communications.

This webinar, led by the Bioceutics team, provides an analysis of targeted therapy communications looking at pharma communication styles, positioning and strategies. It draws insight from the Bioceutics Personalized Healthcare Brand Index Surveillance Report, a first of its kind study of targeted therapies in the marketplace.

Listen to this webinar to learn:

  • An analysis of targeted therapy communications looking at communication styles, positioning and strategies
  • The key drivers in taking a particular communications path
  • What’s working and what’s not working
  • Real world examples and learnings

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications